Immutep Limited (FRA:YP1B)

Germany flag Germany · Delayed Price · Currency is EUR
0.1520
-0.0030 (-1.94%)
Last updated: Oct 22, 2025, 8:07 AM CET
-1.94%
Market Cap251.09M
Revenue (ttm)2.82M
Net Income (ttm)-34.30M
Shares Outn/a
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume70
Open0.1520
Previous Close0.1550
Day's Range0.1520 - 0.1520
52-Week Range0.1080 - 0.2140
Betan/a
RSI63.80
Earnings DateOct 10, 2025

About Immutep

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 31
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol YP1B
Full Company Profile

Financial Performance

In 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.